Keraflex Keratoconus Treatment Study Begins in US

Hersh Vision Group is the First to Offer this Novel Keratoconus Treatment

Avedro, Inc. and Hersh Vision Group announced today that Dr. Peter Hersh has treated the first patient in a physician sponsored Investigational New Drug (IND) study for the Safety and Efficacy of the Keraflex Microwave System. Recruiting for additional eligible patients with keratoconus has now begun.

Dr. Hersh remarked, “Keraflex, combined with corneal collagen cross-linking, is a promising new technology to flatten the protruding cone of keratoconus and make the irregular cornea smoother. Early experience internationally has shown improvements in the keratoconic cornea that we have not seen with past technologies. This should help improve contact lens wear and vision with glasses in patients with keratoconus, a cornea problem that is difficult to correct. We hope that Keraflex can help avoid cornea transplants in many patients who otherwise might have no other alternative.”

The Keraflex refractive correction procedure is a microwave-based, non-incision ophthalmic procedure for flattening the cornea without the removal of tissue. The treatment takes less than a second, and is enhanced through a subsequent treatment of corneal collagen cross-linking using Avedro’s KXL™ accelerated cross-linking system.

“We are pleased that Dr. Hersh is able to offer Keraflex combined with KXL cross-linking as a potential treatment for his keratoconic patients,” said David Muller, PhD, CEO of Avedro. “This system has been in use outside the United States for several years and the initial studies have been very promising.” Peter S. Hersh, M.D. can be reached at the Hersh Vision Group in Teaneck, New Jersey; 201-883-0505; www.vision-institute.com. Keraflex has received CE Mark and is commercially available in over 30 countries. Keraflex is not approved for use in the United States.

About Avedro, Inc.

Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction.

Avedro distributes its products around the world through more than 30 ophthalmic distributors. Avedro’s CE Marked products include capital equipment such as the UV-X devices, the KXL® and KXL II™ Systems, and related proprietary pharmaceuticals such as the VibeX™ and MedioCROSS® formulations. The products are used in a variety of treatments including accelerated cross-linking for keratoconus, Lasik Xtra® and PiXL™. Avedro’s KXL System and pharmaceuticals are being used in Phase III US clinical trials involving over 100 US clinical sites. Avedro products are not for sale in the US.

Contact: David Iannetta; Avedro, Inc.; diannetta@avedro.com; 781‐768‐3400